Oruka Therapeutics, Inc. (ORKA) — 10-Q Filings

10-Q Filings (6)

• ORKA's Losses Widen Amid Increased R&D, Bolstered by $180M PIPE — Nov 12, 2025 Risk: high
  Oruka Therapeutics, Inc. (ORKA) reported a net loss of $30.277 million for the three months ended September 30, 2025, an increase from $28.623 million for the s
• Oruka Therapeutics Reports No Revenue, Focuses on R&D — Aug 11, 2025 Risk: high
  Oruka Therapeutics, Inc. (ORKA) reported no revenue for the quarter ended June 30, 2025, consistent with its pre-commercial stage as a pharmaceutical preparatio
• Oruka Therapeutics Files Q1 2025 10-Q Report — May 14, 2025 Risk: medium
  Oruka Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, formerly known as ARCA biopharma, Inc., NUVEL
• Oruka Therapeutics Files Q3 2024 10-Q Report — Nov 13, 2024 Risk: low
  Oruka Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2024. The company, formerly known as ARCA biopharma, Inc., N
• ARCA biopharma Files 10-Q Amidst Merger Activity — Aug 1, 2024 Risk: medium
  ARCA biopharma, Inc. filed a 10-Q for the period ending June 30, 2024. The company, formerly known as NUVELO INC and HYSEQ INC, is involved in diagnostic substa
• ARCA biopharma, Inc. Files 10-Q for Period Ending March 31, 2024 — Apr 25, 2024 Risk:
  ARCA biopharma, Inc. (ORKA) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. ARCA biopharma, Inc. filed a 10-Q report for the period ending March

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX